Research programme: CX 1000 series - Cylene

Drug Profile

Research programme: CX 1000 series - Cylene

Alternative Names: CX 1000 series; CX 1322

Latest Information Update: 30 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Arizona
  • Developer Cylene Pharmaceuticals; University of Arizona
  • Class Small molecules
  • Mechanism of Action Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Apr 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 15 Oct 2003 Cyternex is now called Cylene Pharmaceuticals
  • 15 Nov 2001 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top